SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
VPHM - Viropharma Inc
An SI Board Since December 1998
Posts SubjectMarks Bans Symbol
2557 72 0 VPHM
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2507Would be niftier if it made toilet water light up fluorescent green if positive rkrw-2/5/2010
2506I would expect little to no difference like the last trial. ===================kenhott-2/5/2010
2505Only thing i see missing here is data non nap1 versus nap1. Last trial there wasrkrw-2/5/2010
2504First glance looks like very good data. SAN DIEGO, Feb. 4 /PRNewswire-FirstCalrkrw-2/4/2010
2503I can tell you the two are seen as interchangeable by thought leaders.rkrw-12/7/2009
2502<i>>… a statistical artifact.</i> Until I see a compelling reasoDewDiligence_on_SI-12/6/2009
2501Well if you subtract one standard deviation from the Cinryze mean (56 ± 36,Biomaven-12/6/2009
2500Thanks for the correction. I don't understand how the half-lives of Cinryze DewDiligence_on_SI-12/4/2009
2499Dew, the numbers used in FDA documents look to be different than those availabletnsaf-12/4/2009
2498<i>>Kalbitor has a half-life of about two hours, while Cinryze has a haDewDiligence_on_SI112/3/2009
2497UPDATE 1-Dyax shrs soar after FDA approves genetic-disorder drug <i>[intetnsaf-12/3/2009
2496PPS $7.00s !mlkr-11/9/2009
2495No message (yet).keokalani'nui-10/13/2009
2494FMR position 8.2M up from 3.4M per 13GIRWIN JAMES FRANKEL-10/13/2009
2493>>Only thing that's puzzling about this approval is it's technicalIRWIN JAMES FRANKEL-10/12/2009
2492Only thing that's puzzling about this approval is it's technically narrorkrw-10/12/2009
2491CSL approved for acute attacks.rkrw-10/11/2009
2490VPHM is gaining PPS, looks like a new base at 9.85.lindalib-10/9/2009
2489Microbiol Immunol. 2009 Oct;53(10):567-72. Antiviral treatments reduce severityscaram(o)uche-10/2/2009
2488Interesting c. Difficile article news.bbc.co.uk C. diff rise due to 'gene rkrw-9/28/2009
2487Patients today already go to ER's or doctor's offices when they have attrkrw-9/28/2009
2486>>Calling the acute indication not clinically viable is strange. Yep. WIRWIN JAMES FRANKEL-9/28/2009
2485Calling the acute indication not clinically viable is strange. I don't thinkrkrw-9/28/2009
2484Nice to see someone upgrading VPHM. CSL non-approval would be particularly niceIRWIN JAMES FRANKEL-9/28/2009
2483Notable Calls has the color on Oppenheimer's upgrade this morning: notablectuck-9/28/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News